UK Markets open in 3 hrs 58 mins
NIKKEI 225
27,382.53 +55.42 (+0.20%) HANG SENG
21,904.33 +62.00 (+0.28%) CRUDE OIL
79.23 +0.36 (+0.46%) GOLD FUTURES
1,942.80 -2.50 (-0.13%) DOW
34,086.04 +368.95 (+1.09%) BTC-GBP
18,782.83 +130.87 (+0.70%)
Karyopharm Therapeutics Inc. (KPTI)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 3.0800 |
| Open | 3.0700 |
| Bid | 3.2300 x 2900 |
| Ask | 3.3000 x 800 |
| Day's range | 3.0700 - 3.3200 |
| 52-week range | 2.4500 - 14.7300 |
| Volume | |
| Avg. volume | 2,746,928 |
| Market cap | 249.307M |
| Beta (5Y monthly) | -0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.7220 |
| Earnings date | 06 Feb 2023 - 10 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.56 |
- Zacks
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Karyopharm Therapeutics (KPTI) points to a 96.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Motley Fool
Karyopharm Therapeutics (KPTI) Q3 2022 Earnings Call Transcript
KPTI earnings call for the period ending September 30, 2022.
- Zacks
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 19.64% and 3.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2023 Yahoo. All rights reserved.
